Caplacizumab is a Monoclonal Antibody owned by Sanofi, and is involved in 13 clinical trials, of which 12 were completed, and 1 is ongoing.
Caplacizumab acts as von Willebrand Factor inhibitor. It binds with high affinity to the A1 domain of von Willebrand Factor (vWF) and thereby blocks the interactions between platelets and vascular collagen. ALX-0681 is an anti-vWF nanobody, which inhibits von Willebrand factor (vWF) and prevent unwanted thrombus formation in vessels under high shear conditions without interfering with desirable haemostasis and to minimize bleeding complications.
The revenue for Caplacizumab is expected to reach a total of $6.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Caplacizumab NPV Report.
Caplacizumab (Cablivi) is an anti-thrombotic agent. It is formulated as lyophilized powder for solution and solution for intravenous and subcutaneous route of administration. Cablivi is indicated for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura. Cablivi (caplacizumab) is indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange and immunosuppressive therapy. It is administered as an intravenous and subcutaneous formulation. The drug candidate is a nanobody targeted against von Willebrand Factor (vWF), a protein found in the blood that acts at a very early stage in the coagulation cascade, namely platelet adhesion. It was also under development for the treatment of acute coronary syndrome (ACS).
Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals and supplements. Sanofi‘s R&D efforts focus on advancing a combination drugs to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.
The company reported revenues of (Euro) EUR39,175 million for the fiscal year ended December 2021 (FY2021), an increase of 4.8% over FY2020. In FY2021, the company’s operating margin was 20.7%, compared to an operating margin of 37.8% in FY2020. In FY2021, the company recorded a net margin of 15.9%, compared to a net margin of 32.9% in FY2020. The company reported revenues of EUR13,138 million for the third quarter ended September 2022, a decrease of 36.8% over the previous quarter.
Quick View – Caplacizumab
|Highest Development Stage|